MetaVia announced positive interim results from its Phase 1 study of DA-1726, showing significant reductions in liver fat and body weight, supporting its potential to treat metabolic and alcohol-associated liver diseases. The company plans to start a 48-week Phase 2 trial in up to 150 patients in the second half of 2027. Additionally, MetaVia appointed Dr. Sarah Browne as Chief Medical Officer to lead clinical development and is advancing another drug, vanoglipel, with a Phase 2a study expected in early 2027. Financially, MetaVia reported increased R&D and administrative expenses and a net loss of $4.6 million for Q3 2026.
MetaVia's Q3 2026 financial results and corporate updates provide context for readers. For those following the health sector, Pluang data shows that out of 150 priced US health stocks, 99 rose and 43 fell today. Notable movers include Heron Therapeutics Inc (HRTX) at USD 0.35 with a 5.80% increase and a typical hold time of 39 days, MiniMed Group Inc. (MMED) at USD 17.00 down 4.90%, and Citius Pharmaceuticals Inc (CTXR) at USD 0.51 down 4.21% with 84% sell order activity, as of Nov 13, 2026 19:41 WIB.
The Beer Institute recognized 16 outstanding professionals with its 2026 BEST IN BREW Honors, celebrating their exceptional contributions across brewing, supply chain, and leadership roles in the U.S. beer industry. This annual award highlights the d...
REalloys Inc. reported a net loss of $30.5 million in Q3 2026 but made significant progress by signing a non-binding term sheet with the U.S. Army for a heavy rare earth processing facility at Tooele Army Depot, Utah. The company is advancing its met...
Modern Mining Technology Corp. began trading on the NYSE American after raising nearly $40 million in an IPO. The company recovers valuable metals like gold, silver, and copper from electronic waste using a proprietary process, avoiding traditional m...
Michelin has disclosed the total number of voting rights and shares composing its capital as of October 31, 2026. The company reported 691,516,292 shares, with theoretical voting rights totaling 980,363,359 and exercisable voting rights at 960,075,64...
Michelin has announced the total number of its voting rights and shares as of October 31, 2026. The company has 691,516,292 shares and 960,075,649 voting rights, considering 20,287,710 treasury shares. This disclosure complies with French regulations...
